GLP-1 Monitoring Protocol: How to Track Your Progress on Semaglutide

Most people on semaglutide or tirzepatide track one thing: the number on the scales. That number matters, but it tells you less than you might think about whether the medication is actually working as intended.

GLP-1 receptor agonists affect body composition, metabolic markers, cardiovascular risk factors, gut motility, and sleep quality. A monitoring protocol that only captures weight misses most of the picture.

This guide sets out a structured approach — what to measure, how often, and what the data means.

The Four Tracking Layers

A complete GLP-1 monitoring protocol has four layers:

1. Weight and body composition — the most visible, but incomplete on its own
2. Blood biomarkers — the metabolic evidence base
3. Physiological markers — HRV, sleep, resting heart rate
4. Symptom and side effect tracking — what the medication feels like

These work together. Weight loss paired with improving lipids, better HRV, and stable kidney function tells a very different story than weight loss with elevated ALT and deteriorating sleep.

Layer 1: Weight and Body Composition

Weight

Weigh yourself weekly, not daily. Daily fluctuations of 1–2 kg are normal (fluid, food volume, time of day). Weekly averages smooth this noise and show the actual trend.

Best practice:

• Same time each week
• Morning, after toilet, before eating
• Same scales
• Record the number and track the 4-week trend

The target trajectory on semaglutide 2.4mg is roughly 0.5–1 kg per week in the early months, slowing as you approach your lower weight. Tirzepatide tends to be faster — the SURMOUNT-1 data showed 20.9% loss at 72 weeks versus 14.9% for semaglutide in STEP 1.

Body Composition

Weight alone does not distinguish between fat loss and muscle loss. This distinction is critical. Research presented at ENDO 2025 found that approximately 40% of the weight lost on semaglutide without intervention is lean mass. Over 20 kg of total loss, that is 8 kg of muscle — enough to meaningfully reduce strength, metabolic rate, and long-term health outcomes.

Body composition tracking options:

• DEXA scan — gold standard, accurate to 1–2%, available privately in most UK cities for around £50–80
• Smart scales with BIA — less accurate but consistent for tracking trends; useful week to week
• Waist and hip measurements — cheap, reliable proxy for visceral fat reduction

A DEXA scan at baseline and at 6 months gives you the most useful data on fat vs muscle changes.

Layer 2: Blood Biomarkers

The blood test schedule is covered in detail at /guides/glp1-blood-test-panel-uk. The summary version:

Before starting: Full panel — HbA1c, lipids, liver (ALT, AST, GGT), kidney (eGFR, creatinine), thyroid (TSH), FBC, ferritin, vitamin D.

At 3 months: HbA1c (particularly important for diabetics whose medication may need adjusting), eGFR and creatinine (dehydration check), fasting glucose.

At 6 months: Full panel repeat. By this point you should see meaningful improvements in:

• HbA1c (if starting above 42 mmol/mol)
• Triglycerides (often reduce 20–30% on semaglutide)
• LDL cholesterol
• ALT (if NAFLD was present)
• Blood pressure (often reduces with weight loss)

What to watch for:

• ALT rising rather than falling: stop alcohol, increase fluid intake, report to prescriber
• eGFR declining: almost always hydration — address fluid intake, repeat in 4 weeks
• Haemoglobin dropping: check ferritin and B12, start supplementation

For testing services in the UK, Lola Health offers comprehensive panels suited to GLP-1 monitoring. See /guides/lola-health-review-glp1 for a full review.

Layer 3: Physiological Markers

This is the tracking layer most people skip — and the one that often provides the earliest signal of whether health is genuinely improving.

Heart Rate Variability (HRV)

HRV is the variation in time between successive heartbeats. Higher HRV correlates with better cardiovascular health, autonomic nervous system function, and recovery capacity. It is one of the most sensitive early indicators of health improvement or deterioration.

On GLP-1 medications, HRV typically improves over weeks to months as weight decreases and metabolic health improves. Tracking it gives you a physiological confirmation that goes beyond the scales.

The Ultrahuman Ring AIR is a wearable ring designed for continuous HRV monitoring, sleep tracking, and metabolic health insights. It runs 24/7, requires no charging breaks, and provides trend data rather than point-in-time measurements.

Sleep Quality

GLP-1 medications improve sleep in multiple ways — through weight loss (reduced sleep apnoea severity), reduced caloric load before bed, and possibly direct neurological effects. Sleep quality often improves noticeably within the first 8–12 weeks.

Track:

• Sleep duration
• Sleep efficiency (time in bed vs time asleep)
• Deep sleep percentage
• Waking episodes

Deteriorating sleep quality on GLP-1 can be a sign of poor nutritional intake (insufficient protein reduces serotonin/melatonin precursors) or electrolyte imbalance from reduced food volume.

Resting Heart Rate

Resting heart rate tends to decrease as cardiovascular fitness improves with weight loss. A weekly average resting heart rate trending down over 3–6 months is a positive sign. A rising resting heart rate can indicate overtraining, illness, or poor recovery.

Layer 4: Symptom Tracking

GLP-1 side effects are common and mostly transient. Tracking them helps distinguish normal adjustment from something that needs attention.

The most common side effects and their usual timeline:

• Nausea: 44% of semaglutide users vs 16% placebo in STEP 1; peaks at dose escalation points, typically resolves within 4–8 weeks of each dose increase
• Constipation: affects 20–25%; often a long-term issue requiring dietary management
• Fatigue: common early; often improves as nutrition optimises
• Headaches: frequently hydration-related; increase fluid intake before reaching for pain relief
• Injection site reactions: mild, transient, usually resolve within a few days

Track symptoms with a simple weekly note. Rate nausea and energy 0–10. This makes it possible to see whether symptoms are genuinely improving over weeks, which they usually do.

For a detailed side effect guide, see /guides/glp1-side-effects-uk.

Building Your Monitoring System

You do not need to track everything at once. Start with the basics and add layers as you go.

Week 1 baseline:

• Weight (record and will repeat weekly)
• Waist measurement
• Blood test panel (Lola Health or similar)
• Start HRV/sleep tracking if you have a wearable

Monthly check-ins:

• Weight trend (4-week average)
• Waist measurement
• Symptom summary (1–10 scores for nausea, energy, sleep, appetite)

3-month review:

• Blood tests: HbA1c, eGFR, creatinine
• Review HRV trend over past 12 weeks
• Adjust protein/electrolyte intake based on any declining markers

6-month review:

• Full blood panel
• DEXA scan if budget allows
• Compare all markers to baseline

What the Numbers Should Be Doing

If the medication is working as expected, by 6 months you should see:

If any marker is moving in the wrong direction, bring it to your prescriber's attention. The most common issues are kidney markers (hydration), liver markers (alcohol interaction or dietary fat), and muscle mass (insufficient protein and resistance training).

For detailed guidance on protein intake, see /blog/protein-on-glp1-complete-guide.

The Compound Effect of Good Monitoring

The people who get the best outcomes on GLP-1 are not necessarily the ones on the highest dose. They are the ones who treat monitoring as part of the intervention, not an afterthought.

Knowing your body composition splits means you respond appropriately when lean mass starts declining. Knowing your HRV trend means you can catch signs of overtraining or poor recovery before they become problems. Knowing your ALT baseline means elevated liver enzymes prompt action rather than uncertainty.

The medication does the metabolic heavy lifting. Your job is to create the conditions — nutrition, training, hydration, monitoring — that let it work as well as possible.